Katherine Stultz
Direktor/Vorstandsmitglied bei KRONOS BIO, INC.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Geoffrey Harris | M | - |
Ocelot Bio, Inc.
 Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | - |
| David Tanen | M | 52 | 7 Jahre | |
| David Elkins | M | 55 | 6 Jahre | |
| Arie Belldegrun | M | 74 | 7 Jahre | |
| Joshua Kazam | M | 47 | 7 Jahre | |
| Allison Frisbee | F | 41 | 4 Jahre | |
| Norbert W. Bischofberger | M | 68 | 6 Jahre | |
| Tai Yin Yang | M | 70 | 3 Jahre | |
| Elizabeth A. Olek | M | 59 | 2 Jahre | |
| P. Joseph Campisi | M | - | 5 Jahre | |
| Roger Dansey | M | 68 | 1 Jahre | |
| Katherine Reynolds Kelly | F | 48 | 5 Jahre | |
| Roshawn Blunt | F | 49 | 3 Jahre | |
| Matt Roden | M | 53 | 5 Jahre | |
| Elena Ridloff | F | 44 | 4 Jahre | |
| Sandra Gardiner | F | 58 | 1 Jahre | |
| Donald Santel | M | 62 |
Ocelot Bio, Inc.
Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | 3 Jahre |
| Jack Nielsen | M | 60 |
Ocelot Bio, Inc.
Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | 3 Jahre |
| Ann Li Lee | M | 63 | 6 Jahre | |
| Rocio Martin Hoyos | F | - | 3 Jahre | |
| Camille Samuels | F | 52 |
Ocelot Bio, Inc.
Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | - |
| Jack Nielsen | M | - |
Ocelot Bio, Inc.
Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | - |
| Charles Lin | M | 39 | 5 Jahre | |
| Jeffrey Galik | M | - | 5 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Mark Alles | M | 64 | 15 Jahre | |
| Sol Barer | M | 76 | 25 Jahre | |
| Robert Hugin | M | 69 | 19 Jahre | |
| Jacqualyn Fouse | M | 62 | 7 Jahre | |
| Jonathan Biller | M | 61 | 8 Jahre | |
| Phillip Gutry | M | 50 | - | |
| Perry Karsen | M | 69 | 9 Jahre | |
| Peter Kellogg | M | 67 | 5 Jahre | |
| Thomas Daniel | M | 69 | 10 Jahre | |
| Kristen Hege | M | 60 | 9 Jahre | |
| Barbara Kosacz | F | 66 | 4 Jahre | |
| Timothy J. Smith | M | - | - | |
| Scott Smith | M | 61 | 10 Jahre | |
| Jorge DiMartino | M | 60 | 13 Jahre | |
| Yasir Al-Wakeel | M | 42 | 3 Jahre | |
| Jay Backstrom | M | 69 | 11 Jahre | |
| Carrie Cox | F | 66 | 10 Jahre | |
| Marni Kottle | F | - | 3 Jahre | |
| Sandy Mahatme | M | 59 | 6 Jahre | |
| Thomas Perone | M | 59 | 12 Jahre | |
| Smital Shah | F | 48 | - | |
| Marianne de Backer | M | 55 | 2 Jahre | |
| Gerald F. Masoudi | M | 56 | 3 Jahre | |
| Brendan Delaney | M | 49 | 6 Jahre | |
| Julia Haller | M | 69 | - | |
| Rupert Vessey | M | 59 | 4 Jahre | |
| Michael Friedman | M | 80 | 8 Jahre | |
| Joanne Viney | M | 58 | - | |
| Patrick E. Flanigan | M | - | - | |
| John W. Jackson | M | 78 | 10 Jahre | |
| John Weiland | M | 68 | 1 Jahre | |
| Michael Bonney | M | 65 | 4 Jahre | |
| Richard Morgan | M | 79 | 29 Jahre | |
| Patricia Hemingway Hall | F | 71 | 1 Jahre | |
| Jacquelyn Sumer | F | 46 | 1 Jahre | |
| Gilla Kaplan | M | 76 | 20 Jahre | |
| William Rastetter | M | 76 | 6 Jahre | |
| Ernest Mario | M | 85 | 12 Jahre | |
| Rodman L. Drake | M | 80 | 8 Jahre | |
| Michael D. Casey | M | 78 | 17 Jahre | |
| Richard W. Barker | M | 75 | 7 Jahre | |
| James J. Loughlin | M | 81 | 12 Jahre | |
| Lawrence V. Stein | M | 74 | 3 Jahre | |
| Robert Hershberg | M | 61 | 5 Jahre | |
| George Matcham | M | 72 | 30 Jahre | |
| Jennifer Dudinak | M | - | 1 Jahre | |
| Carrie Brownstein | M | 54 | 3 Jahre | |
| Anjan G. Thakurta | M | - | 6 Jahre | |
| Neil S. Belloff | M | 64 | - | |
| Joanne Beck | M | 63 | 3 Jahre | |
| Ernie Meyer | M | 60 | 2 Jahre | |
| Aleksandra Rizo | M | 49 | 1 Jahre | |
| Robert Knight | M | 73 | 16 Jahre | |
| Michele Korfin | F | 53 | 12 Jahre | |
| Deanna Weber | F | - | - | |
| Aijaz Tobaccowalla | M | - | 1 Jahre | |
| Frank T. Cary | M | 103 | 19 Jahre | |
| Andrew W. Lam | M | - | 1 Jahre | |
| John D. Soriano | M | 62 | 7 Jahre | |
| Richard Bagger | M | 63 | 7 Jahre | |
| Karen Brophy | F | 60 | 6 Jahre | |
| Arthur Hull Hayes | M | 89 | 15 Jahre | |
| Walter L. Robb | M | 95 | 19 Jahre | |
| Martin Vogelbaum | M | 60 | 2 Jahre | |
| Isaac E. Ciechanover | M | 53 | 6 Jahre | |
| Joseph S. Camardo | M | 69 | 10 Jahre | |
| Jerome Zeldis | M | 74 | 19 Jahre | |
| Amy Edmonds | F | 52 | 10 Jahre | |
| David R. Webb | M | 79 | 8 Jahre | |
| Thomas Bock | M | 60 | 3 Jahre | |
| Michael N. Needle | M | 64 | 6 Jahre | |
| Randall M. Stevens | M | - | - | |
| Shawn Tomasello | F | 65 | 9 Jahre | |
| Julia Tran | F | 47 | 2 Jahre | |
| Alise Reicin | M | 63 | 1 Jahre | |
| Edward Dulac | M | 49 | 8 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Katherine Stultz
- Persönliches Netzwerk
